<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00695539</url>
  </required_header>
  <id_info>
    <org_study_id>NIS-CGR-CRE-2007/1</org_study_id>
    <nct_id>NCT00695539</nct_id>
  </id_info>
  <brief_title>Rosuvastatin Efficacy and Safety Evaluation in Hypercholesterolaemic Patients</brief_title>
  <acronym>RESEARCH</acronym>
  <official_title>A Multi-centre, Open Label, Non-randomised, Non Interventional, 24 Weeks Study for the Efficacy and Safety of Rosuvastatin Following Its Administration in Real Life Clinical Practice in Greek Hypercholesterolaemic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-arm, phase IV, open-label, prospective, non interventional study to evaluate
      the efficacy, tolerability and safety of rosuvastatin administered for 24 weeks in
      approximately 900 Greek subjects with hypercholesterolemia under normal clinical practice.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The assessment of rosuvastatin efficacy in the reduction of low-density lipoprotein cholesterol (LDL-C) in subjects with hypercholesterolemia at week 12 of treatment compared with baseline</measure>
    <time_frame>At 12 weeks of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the percentage of patients on European LDL-C target at week 12</measure>
    <time_frame>At 12 weeks of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in HDL-C, TC and TG</measure>
    <time_frame>At week 12 &amp; 24 of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>Throughout the study</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">810</enrollment>
  <condition>Hypercholesterolaemia</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Primary Care
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with hypercholesterolaemia who are already in treatment with rosuvastatin
             according to the approved SPC for no longer than 1 month prior to study entry

          -  Patients that are able to read, understand and sign the Patient Information &amp; Consent
             Form

          -  Patients that are willing to comply with all study requirements

        Exclusion Criteria:

          -  Patients that are likely not to comply with all study requirements

          -  Patients that currently participate or have participated in a 3 months period prior to
             study entry in another clinical trial

          -  Female of child bearing potential that do not use a reliable method of contraception.
             Pregnancy or lactation.

          -  Patients that meet any of the contraindications described in the approved SPC
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Alexandroupoli</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Iraklio, Crete</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Larissa</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rio, Patra</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Thessaloniki</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>October 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 10, 2008</study_first_submitted>
  <study_first_submitted_qc>June 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 12, 2008</study_first_posted>
  <last_update_submitted>October 2, 2009</last_update_submitted>
  <last_update_submitted_qc>October 2, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 5, 2009</last_update_posted>
  <responsible_party>
    <name_title>Panagiotis Pontikis, MD, Medical &amp; Regulatory Affairs Director, AstraZeneca Greece</name_title>
    <organization>AstraZeneca S.A., Greece</organization>
  </responsible_party>
  <keyword>Rosuvastatin</keyword>
  <keyword>hypercholesterolaemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

